GE Healthcare’s AIR Recon DL gets US FDA Approval for 3D and Motion Insensitive Imaging Applications


GE Healthcare announced that the US Food and Drug Administration (FDA) has cleared its AIR Recon DL for 3D and PROPELLER imaging sequences. The advantages of AIR Recon DL are extended by the new features to cover all Magnetic Resonance Imaging (MRI) clinical procedures, which covers all anatomies and enables better image quality, enhanced patient experience, and short scanning time.

The AIR Recon DL is a deep learning-based image reconstruction technology for MRI, and has shifted the balance between scan time and image quality fundamentally. Now, with the expanded compatibility from 2D to 3D imaging sequences, physicians can quickly diagnose patients with an improved signal-to-noise ratio (SNR).

Additionally, AIR Recon DL is also compatible with PROPELLER, which is a motion-insensitive imaging sequence that is important for anatomies susceptible to motion like MRI exams, geriatric, and claustrophobic patients who have difficulty remaining still for the duration of an MRI scan.

As of September 2022, around 3.5 million patients across the globe have been scanned with AIR Recon DL. According to a study, 100 percent of the participants said the AIR Recon DL provides better SNR and has equivalent image sharpness than the reconstruction of conventional image.

READ  US Government Announced Plans to Share 55-Million Covid-19 Vaccine Doses Globally

According to the study, 99 percent participants said the AIR Recon DL provides 50 percent reduction in exam times, and create efficiency in workflow, with increase in productivity.